AUR-AD9E-TTM1-A-1-1-R-A542-39
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- G2M_CHECKPOINT+0.460
- MYC_TARGETS_V2+0.400
- MYC_TARGETS_V1+0.350
- DNA_REPAIR+0.340
- MITOTIC_SPINDLE+0.330
- PANCREAS_BETA_CELLS+0.310
- TGF_BETA_SIGNALING+0.300
- OXIDATIVE_PHOSPHORYLATION+0.190
- SPERMATOGENESIS+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.580
- IL6_JAK_STAT3_SIGNALING-0.490
- INFLAMMATORY_RESPONSE-0.470
- COMPLEMENT-0.410
- TNFA_SIGNALING_VIA_NFKB-0.350
- FATTY_ACID_METABOLISM-0.270
- IL2_STAT5_SIGNALING-0.260
- XENOBIOTIC_METABOLISM-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6079988 | — | — | 0.882 |
| 2 | TCGA-77-8128-01A-11R-2247-07 | — | cohortSQ2 | 0.881 |
| 3 | R399 | — | — | 0.874 |
| 4 | SRR8518449 | — | E | 0.869 |
| 5 | BS_MDBT7S5Z | high-grade glioma | — | 0.866 |
| 6 | SRR8518411 | — | E | 0.863 |
| 7 | TCGA-A8-A07L-01A-11R-A00Z-07 | — | B | 0.859 |
| 8 | f2c3b90a.7e75.4a2a.925e.29eb9a2acac2 | — | cohortA3 | 0.859 |
| 9 | SRR35579809 | — | B | 0.848 |
| 10 | TCGA-50-5931-01A-11R-1755-07 | — | cohortMD1 | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.010 | Inavolisib | — uncovered |